Table 2.
Clinical outcomes according to high- and low-risk HPV genotypes of the tumors of patients with HPV-positive HNSCCs
| Variable | HPV-positive HNSCC | HR HPV (n = 134) | LR HPV (n = 11) | p value |
|---|---|---|---|---|
| Response to induction chemotherapy | ||||
| CR/nCR | 8 (15.7) | 6 (13.0) | 0 | 0.229 |
| PR | 30 (58.8) | 28 (60.9) | 1 (50.0) | |
| SD | 6 (11.8) | 6 (13.0) | 0 | |
| PD | 4 (7.8) | 4 (8.7) | 0 | |
| NE | 3 (5.9) | 2 (4.4) | 1 (50.0) | |
| Response to treatment | ||||
| CR/nCR | 135 (88.8) | 119 (88.8) | 9 (81.8) | 0.218 |
| PR | 10 (6.6) | 9 (6.7) | 1 (9.1) | |
| SD | 0 | 0 | 0 | |
| PD | 4 (2.6) | 4 (3.0) | 0 | |
| NE | 3 (2.0) | 2 (1.5) | 1 (9.1) | |
| Disease status | ||||
| Relapse | 32 (21.1) | 27 (20.12) | 3 (27.3) | 0.769 |
| Progression in non-CR | 12 (7.9) | 11 (8.2) | 1 (9.1) | |
| No relapse nor progression | 108 (71.0) | 96 (71.6) | 7 (63.6) | |
| Relapse site | ||||
| Locoregional | 25 (16.7) | 20 (15.2) | 4 (36.4) | 0.482 |
| Distant | 8 (5.3) | 7 (5.3) | 0 | |
| Both | 4 (2.7) | 4 (3.0) | 0 | |
| Death | 6 (4.0) | 6 (4.5) | 0 | |
| None | 107 (71.3) | 95 (72.0) | 7 (63.6) | |
| Disease-free survival, mon, median (95% CI) | NR (75.0–NR) | NR (75.0–NR) | 44.4 (9.3–NR) | 0.286 |
| Death | ||||
| Yes | 26 (17.1) | 23 (17.2) | 1 (9.1) | 0.692 |
| No (censored) | 126 (82.9) | 111 (82.8) | 10 (90.9) | |
| Overall survival, mon, median (95% CI) | NR (115.8–NR) | NR (12.6–NR) | NR (115.8–NR) | 0.753 |
| Follow-up duration, mon, median (range) | 29.5 (2.2–205.9) | 30.3 (2.2–205.9) | 21.3 (9.4–73.7) |
Values are presented as number (%) unless otherwise indicated.
HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma; HR, high-risk; LR, low-risk; CR, complete response; nCR, near complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; NR, not reached; CI, confidence interval.